DISCOVER THE IMPACT OF GEMTESA: A Selective ?3-Adrenergic Agonist for Effective OAB Treatment

Overview

OAB remains underdiagnosed and undertreated, with high medication–discontinuation rates among patients who are treated. In this program, the faculty will discuss unmet needs in OAB management and present clinical data on a ?3-adrenergic receptor agonist for the treatment of OAB. Illustrative patient case studies will be featured throughout the presentation. This non-CME program is sponsored by Sumitomo Pharma America, Inc.